Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06627647 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 295 → 300 locations Eligibility criteria expanded, about 16 words · Secondary endpoints: details revised at 3 of 10 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 3 of 10 entries
  2. Trial sites expanded: 287 → 295 locationsv17
  3. Enrollment increased: 878 → 1160 participants Study sites: 286 to 287 · Secondary endpoints: details revised at 10 of 10 entries · Eligibility criteria expanded, about 4 words · 2 morev16 Show 5 more changesShow less
    • Study sites: 286 to 287
    • Secondary endpoints: details revised at 10 of 10 entries
    • Eligibility criteria expanded, about 4 words
    • Study description expanded, about 4 words
    • Study title expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion pushed from May 10, 2029 to Nov 18, 2030 Trial sites expanded: 283 → 286 locations · Completion pushed from Mar 25, 2030 to Nov 18, 2030v15 Show 2 more changesShow less
    • Trial sites expanded: 283 → 286 locations
    • Completion pushed from Mar 25, 2030 to Nov 18, 2030
  5. Study sites: 282 to 283v14
Show 12 earlier versionsHide 12 earlier versions
  1. Site details revised at 7 of 282 sitesv13
  2. Study sites: 281 to 282v12
  3. Study sites: 279 to 281v11
  4. Study sites: 276 to 279v10
  5. Study sites: 275 to 276v9
  6. Site details revised at 21 of 275 sitesv8
  7. Study sites: 271 to 275v7
  8. Study sites: 261 to 271v6
  9. Study sites: 241 to 261 Secondary endpoints: details revised at 1 of 10 entries · Eligibility criteria expanded, about 5 wordsv5 Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 10 entries
    • Eligibility criteria expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  10. Study sites: 227 to 241 Completion date: Mar 20, 2030 to Mar 25, 2030v4 Show 1 more changeShow less
    • Completion date: Mar 20, 2030 to Mar 25, 2030
  11. Study sites: 211 to 227 Primary completion date: May 14, 2029 to May 10, 2029 · Completion date: Mar 25, 2030 to Mar 20, 2030v3 Show 2 more changesShow less
    • Primary completion date: May 14, 2029 to May 10, 2029
    • Completion date: Mar 25, 2030 to Mar 20, 2030
  12. Trial status: Not Yet Recruiting to Recruiting Study sites: 148 to 211 · Start date changed from estimate of Nov 29, 2024 to Nov 27, 2024 · Secondary endpoints: 11 to 10v2 Show 3 more changesShow less
    • Study sites: 148 to 211
    • Start date changed from estimate of Nov 29, 2024 to Nov 27, 2024
    • Secondary endpoints: 11 to 10

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.
Trial Details
NCT Number NCT06627647
Lead Sponsor AstraZeneca
Conditions Non-squamous Non-small Cell Lung Cancer
Enrollment 1,160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov